| Stephen Alan South, MD | |
|
2703 Henry St, Greensboro, NC 27405-3669 | |
| (336) 621-8911 | |
| (336) 621-6322 |
| Full Name | Stephen Alan South |
|---|---|
| Gender | Male |
| Speciality | Endocrinology |
| Experience | 37 Years |
| Location | 2703 Henry St, Greensboro, North Carolina |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1043237472 | NPI | - | NPPES |
| 897844A | Medicaid | NC |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207RE0101X | Internal Medicine - Endocrinology, Diabetes & Metabolism | 35210 (North Carolina) | Primary |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Guilford Medical Associates Pa | 9537197231 | 11 |
News Archive
Medivation, Inc. and Astellas Pharma Inc. today announced treatment of the first patient in a second Phase 3 clinical trial of the investigational drug MDV3100, which expands the Phase 3 development of the novel, triple-acting oral androgen receptor antagonist into an earlier-stage patient population. Known as PREVAIL, the trial will evaluate MDV3100 in men with advanced prostate cancer who have not yet received chemotherapy. Initiation of the PREVAIL trial triggers a milestone payment to Medivation under its collaboration agreement with Astellas.
Amanda Glassman and Jenny Ottenhoff of the Center for Global Development (CGD) write in the CGD's "Global Health Policy" blog about "the tough trade-offs the Office of Management and Budget (OMB) must be considering as they finalize the president's FY14 budget request to Congress, expected to be released in mid-March."
Verastem, Inc., a biopharmaceutical company focused on discovering and developing drugs to treat cancer by targeting cancer stem cells, today announced the closing of a $16 million Series A financing. Founding investor, Longwood Founders Fund, was joined by Bessemer Venture Partners, Cardinal Partners, and MPM Capital.
A new study led by Mayo Clinic researchers has found that relief of pain from vertebral compression fractures, as well as improvement in pain-related dysfunction, were similar in patients treated with vertebroplasty and those treated with simulated vertebroplasty without cement injections. The article, "A Randomized Controlled Trial of Vertebroplasty for Osteoporotic Spine Fractures," was released today in the New England Journal of Medicine.
› Verified 4 days ago
| Entity Name | Guilford Medical Associates Pa |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1093731671 PECOS PAC ID: 9537197231 Enrollment ID: O20050803000501 |
News Archive
Medivation, Inc. and Astellas Pharma Inc. today announced treatment of the first patient in a second Phase 3 clinical trial of the investigational drug MDV3100, which expands the Phase 3 development of the novel, triple-acting oral androgen receptor antagonist into an earlier-stage patient population. Known as PREVAIL, the trial will evaluate MDV3100 in men with advanced prostate cancer who have not yet received chemotherapy. Initiation of the PREVAIL trial triggers a milestone payment to Medivation under its collaboration agreement with Astellas.
Amanda Glassman and Jenny Ottenhoff of the Center for Global Development (CGD) write in the CGD's "Global Health Policy" blog about "the tough trade-offs the Office of Management and Budget (OMB) must be considering as they finalize the president's FY14 budget request to Congress, expected to be released in mid-March."
Verastem, Inc., a biopharmaceutical company focused on discovering and developing drugs to treat cancer by targeting cancer stem cells, today announced the closing of a $16 million Series A financing. Founding investor, Longwood Founders Fund, was joined by Bessemer Venture Partners, Cardinal Partners, and MPM Capital.
A new study led by Mayo Clinic researchers has found that relief of pain from vertebral compression fractures, as well as improvement in pain-related dysfunction, were similar in patients treated with vertebroplasty and those treated with simulated vertebroplasty without cement injections. The article, "A Randomized Controlled Trial of Vertebroplasty for Osteoporotic Spine Fractures," was released today in the New England Journal of Medicine.
› Verified 4 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Stephen Alan South, MD Po Box 14944, Greensboro, NC 27415-4944 Ph: (336) 621-8911 | Stephen Alan South, MD 2703 Henry St, Greensboro, NC 27405-3669 Ph: (336) 621-8911 |
News Archive
Medivation, Inc. and Astellas Pharma Inc. today announced treatment of the first patient in a second Phase 3 clinical trial of the investigational drug MDV3100, which expands the Phase 3 development of the novel, triple-acting oral androgen receptor antagonist into an earlier-stage patient population. Known as PREVAIL, the trial will evaluate MDV3100 in men with advanced prostate cancer who have not yet received chemotherapy. Initiation of the PREVAIL trial triggers a milestone payment to Medivation under its collaboration agreement with Astellas.
Amanda Glassman and Jenny Ottenhoff of the Center for Global Development (CGD) write in the CGD's "Global Health Policy" blog about "the tough trade-offs the Office of Management and Budget (OMB) must be considering as they finalize the president's FY14 budget request to Congress, expected to be released in mid-March."
Verastem, Inc., a biopharmaceutical company focused on discovering and developing drugs to treat cancer by targeting cancer stem cells, today announced the closing of a $16 million Series A financing. Founding investor, Longwood Founders Fund, was joined by Bessemer Venture Partners, Cardinal Partners, and MPM Capital.
A new study led by Mayo Clinic researchers has found that relief of pain from vertebral compression fractures, as well as improvement in pain-related dysfunction, were similar in patients treated with vertebroplasty and those treated with simulated vertebroplasty without cement injections. The article, "A Randomized Controlled Trial of Vertebroplasty for Osteoporotic Spine Fractures," was released today in the New England Journal of Medicine.
› Verified 4 days ago
Dr. Olugbemiga Ebenezer Jegede, M.D Endocrinology, Diabetes & Metabolism Medicare: Accepting Medicare Assignments Practice Location: 201 E Wendover Ave, Greensboro, NC 27401 Phone: 336-832-4444 Fax: 336-832-4445 | |
Yan Feng, Endocrinology, Diabetes & Metabolism Medicare: Accepting Medicare Assignments Practice Location: 501 N Elam Ave, Greensboro, NC 27403 Phone: 336-832-1100 | |
Dr. Gary Bradley Sherrill, M.D. Endocrinology, Diabetes & Metabolism Medicare: Accepting Medicare Assignments Practice Location: 501 N Elam Ave, Greensboro, NC 27403 Phone: 336-832-1100 | |
Edwin Aziegbe Avbuere, MD Endocrinology, Diabetes & Metabolism Medicare: Accepting Medicare Assignments Practice Location: 3231 Yanceyville Street, Greensboro, NC 27405 Phone: 336-358-1528 Fax: 336-358-1582 | |
Dr. Jay Krishnavadan Patel, MB.CHB Endocrinology, Diabetes & Metabolism Medicare: Accepting Medicare Assignments Practice Location: 309 New St, Carolina Kidney Associates, Greensboro, NC 27405 Phone: 336-379-9708 Fax: 336-553-2085 | |
Gayatri A Acharya, MD Endocrinology, Diabetes & Metabolism Medicare: Accepting Medicare Assignments Practice Location: 3200 Northline Ave Ste 250, Greensboro, NC 27408 Phone: 336-273-7900 | |
Murali Ramaswamy, MD FAAFP Endocrinology, Diabetes & Metabolism Medicare: Accepting Medicare Assignments Practice Location: 520 N Elam Ave, Greensboro, NC 27403 Phone: 336-547-1801 Fax: 336-547-1828 |